Assay ID | Title | Year | Journal | Article |
AID1381729 | Inhibition of Leishmania major PTR1 at 50 uM using H2B as substrate in presence of NADPH by photometric analysis relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381712 | Cytotoxicity against human U2OS cells assessed as viable cells at 50 uM after 72 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381710 | Cytotoxicity against human 786-O cells assessed as inhibition of mitochondrial viability at 10 uM after 6 hrs by CMXRos staining based assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381711 | Cytotoxicity against human THP1 cells assessed as viable cells at 100 uM after 72 hrs by MTT assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536024 | Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability at 40 uM after 11 days by trypan blue exclusion assay | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381716 | Selectivity index, ratio of CC50 for human U2OS cells to EC50 for Trypanosoma cruzi amastigote form | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536021 | Inhibition of Trypanosoma cruzi cruzaine pre-incubated for 10 mins | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381691 | Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form after 72 hrs by SYBR Green assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536027 | Cytotoxicity against BALB/c mouse Splenocyte assessed as non-cytotoxic concentration after 24 hrs by [3H]-thymidine incorporation assay relative to control | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381715 | Cytotoxicity against human U2OS cells assessed as decrease in viable cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536020 | Inhibition of Trypanosoma cruzi cruzaine at 100 uM pre-incubated for 10 mins | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381689 | Antileishmanial activity against Leishmania infantum amastigote form assessed as parasite growth inhibition at 50 uM after 72 hrs by steady-Glo reagent based assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381704 | Inhibition of human microsomal CYP2C19 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536025 | Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as viability after 11 days by trypan blue exclusion assay | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381728 | Inhibition of Trypanosoma brucei PTR1 at 50 uM using H2B as substrate in presence of NADPH by photometric analysis relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381705 | Inhibition of human microsomal CYP2D6 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381690 | Antitrypanosomal activity against Trypanosoma cruzi amastigote form infected in human U2OS cells assessed as parasite growth inhibition at 50 uM after 72 hrs relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381703 | Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1233717 | Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability incubated for 24 hrs by beta-radiation counting based [3H]-thymidine incorporation assay | 2015 | European journal of medicinal chemistry, Jul-15, Volume: 100 | Thiosemicarbazones as Aedes aegypti larvicidal. |
AID1381696 | Inhibition of human microsomal CYP1A2 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381702 | Inhibition of human ERG at 10 uM incubated for 2 hrs by fluorescence polarisation assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381693 | Antitrypanosomal activity against Trypanosoma cruzi amastigote form infected in human U2OS cells assessed as parasite growth inhibition after 72 hrs | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1571731 | Reversible mixed-type inhibition of mushroom tyrosinase by Lineweaver-Burk plot analysis | 2019 | MedChemComm, Mar-01, Volume: 10, Issue:3
| Thiosemicarbazones with tyrosinase inhibitory activity. |
AID1233716 | Larvicidal activity against Aedes aegypti L4 stage larvae assessed as induction of larval mortality incubated for 48 hrs | 2015 | European journal of medicinal chemistry, Jul-15, Volume: 100 | Thiosemicarbazones as Aedes aegypti larvicidal. |
AID1381695 | Potentiation of methotrexate-induced antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID625341 | Inhibition of jack bean urease assessed as ammonia production after 30 mins by indophenol method | 2011 | European journal of medicinal chemistry, Nov, Volume: 46, Issue:11
| Synthesis, biological assay in vitro and molecular docking studies of new Schiff base derivatives as potential urease inhibitors. |
AID1381697 | Potentiation of methotrexate-induced antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536019 | Inhibition of Trypanosoma cruzi cruzaine in presence of 0.01% Triton X-100 | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381688 | Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form assessed as parasite growth inhibition at 50 uM after 72 hrs by SYBR Green assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381706 | Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381694 | Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream form at 10 uM after 72 hrs by resazurin dye-based assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381708 | Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM after 48 hrs by CellTiter-Glo assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID536026 | Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y assessed as viability after 24 hrs by trypan blue exclusion assay | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID536023 | Inhibition of Trypanosoma cruzi cruzaine in absence of 0.01% Triton X-100 | 2010 | Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
| Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. |
AID1381707 | Inhibition of recombinant full-length human aurora B kinase expressed in baculovirus system at 10 uM using MBP as substrate incubated for 45 mins by ADP-glo kinase assay | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID1381709 | Cytotoxicity against human WI38 cells assessed as growth inhibition at 10 uM after 48 hrs by CellTiter-Glo assay relative to control | 2018 | European journal of medicinal chemistry, Feb-25, Volume: 146 | Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |